Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565115 | 1.00 | DRD2 (0.51) | DRD2DRD3CHRNA7KDM1AHTR6 | |
| Hydrochloric Acid SCHEMBL10357354 | 0.98 | DRD2 (0.50) | DRD2DRD3CHRNA7KDM1AHTR6 | |
| SCHEMBL30563632 | 0.90 | DRD2 (0.58) | DRD2DRD3CHRNA7ACHEHTR2C | |
| SCHEMBL268865 | 0.90 | DRD2 (0.58) | DRD2DRD3CHRNA7ACHEHTR2C | |
| SCHEMBL26962573 | 0.90 | DRD2 (0.58) | DRD2DRD3CHRNA7ACHEHTR2C | |
| Hydrochloric Acid SCHEMBL30563624 | 0.88 | DRD2 (0.57) | DRD2DRD3CHRNA7ACHEHTR2C | |
| Hydrochloric Acid SCHEMBL26962665 | 0.88 | DRD2 (0.57) | DRD2DRD3CHRNA7ACHEHTR2C | |
| Hydrochloric Acid SCHEMBL1915095 | 0.88 | DRD2 (0.57) | DRD2DRD3CHRNA7ACHEHTR2C | |
| Hydrochloric Acid SCHEMBL31186920 | 0.88 | DRD2 (0.57) | DRD2DRD3CHRNA7ACHEHTR2C | |
| SCHEMBL1237849 | 0.87 | ACHE (0.62) | DRD2DRD3CHRNA7KDM1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| EP-3946299-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2022-02-09 | — | — | EP | disclosed |
| CN-113660932-A | Phenyl derivatives with pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0179667-B1 | N6-SUBSTITUTED ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0006217-B1 | SUBSTITUTED AMINO ACIDS, THEIR USE AND PREPARATION, AND COMPOSITIONS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-31 | — | — | EP | disclosed |
| US-4243678-A | GASTROINTESTINAL DISORDERS, LIVER DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| EP-0006217-A1 | Substituted amino acids, their use and preparation, and compositions containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | DRD2 3800/4885DRD3 3747/4885CHRNA7 592/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | DRD2 3330/4885DRD3 2901/4885CHRNA7 670/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | DRD2 2743/4885DRD3 3244/4885CHRNA7 689/4885 |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | AADAC, ENPP2, ATXN10 | DRD2 3330/4885DRD3 2901/4885CHRNA7 670/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | DRD2 3800/4885DRD3 3747/4885CHRNA7 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.